



Definition of Personalised Medicine and the value for healthcare systems & Summary of the EP PerMed draft concept document

Personalised Medicine (PM) is as a major opportunity for society to provide benefits to patients and citizens and health systems. Key questions that PM tackles are:

- **Why does a treatment for a certain disease work very well for one patient, but poorly or not at all for another patient?**
- **What is the benefit of individual molecular, clinical or lifestyle data for the development of personalised prevention, diagnostics, and treatment?**
- **How can the knowledge of an individual genetic profile or personal setting help to avoid health risks and support a healthy life?**
- **Can the use of PM be cost effective?**

There is a common understanding among researchers, healthcare providers and other stakeholders that PM, due to its great potential for disease prevention, diagnostic and treatment, is a principal driver towards optimised healthcare. But is Europe, with its heterogeneous regional and national healthcare systems, prepared for this improvement?

Major progress has already been achieved via many international, pan-European, national as well as regional initiatives. To further develop and promote implementation of PM approaches, and to address the challenge “to not leave anyone behind”, joint efforts are needed among all key European stakeholders.

This can be achieved through a co-funded European Partnership for Personalised Medicine (EP PerMed) bringing together commitments of EU member states and participating organisations. The inputs will be sharing of information, evidence, know-how and the willingness to cooperate as well as contribution of resources in form of personnel, cash, in-kind and additional co-funding support by the European Commission.


With these inputs, EP PerMed will be a prime driver for developing and implementing PM by establishing priorities for **research funding, aligning PM strategies, developing educational and literacy strategies, and supporting policy development**. These activities are based on current initiatives like ICPeMed and ERA PerMed whose efforts will be further developed within EP PerMed to:

- Develop, promote, and support innovative PM solutions and implementation strategies.
- Promote, align, and encourage joint funding efforts within PM research and implementation.
- Promote the advances of PM as well as the state-of-the-art understanding by facilitating exchange of information, experiences, and ideas.

- Accelerate the discussion and decision-making by providing a platform for all key players and institutions involved in the PM research and implementation, including patient and citizen representatives.
- Support the communication and collaboration amongst European countries and regions at multiple levels.
- Strengthen the communication and collaboration between European authorities and international partners, as well as complementary initiatives and relevant stakeholders.

With seven years of funding and a steadily advancing PM environment, the EP PerMed platform, with its structure around the described four main activities and joint coordination and management, will act in a flexible and dynamic way to allow continuous adaption of the focus.

Research and Innovation towards PM Implementation in Healthcare



Comment: For more detailed information please see also Annex 7.1 of the draft concept document.

EP PerMed will support cooperation and investment across Europe and thus pave the way towards the efficient use of existing healthcare systems for the citizens, support translation of innovation to the market, foster a highly connected PM ecosystem, also on the national levels, and support increased literacy of citizens and health professionals. Hence, EP PerMed will influence the transformation of research and health care.

EP PerMed will create innovation and value by dedicated PM research funding activities, by developing new implementation tools, scientific concepts, knowledge bases, health economic models, etc. for implementation of PM in health care. This includes also social innovation to meet social needs for example around education and literacy and the development of a PM community along the whole value chain with active participation of patients and citizens.

The work of EP PerMed will lead to a harmonised PM research and implementation in health systems across Europe, facilitate the uptake of PM innovation by health systems and establish a common language and understanding on PM for citizens, patients and health professionals. EP PerMed will have a major impact on enabling PM implementation for citizens ensuring that Europe is at the forefront of PM research and innovation.

This Information Sheet is the result of ICPeMed/ERA PeMed reflections on EP PeMed aspects. The concept, legal and financial frameworks for the EP PeMed are still under development (e.g. governance, partner/member/stakeholder rules for participation, etc.), and the Information Sheet will be adapted in the future to integrate and outline such technical aspects when relevant. The Information Sheet received valuable input from the European Commission (EC) but does not represent an official EC document.

Contact details of the ICPeMed/ERA PeMed preparatory group:

- ICPeMed: ICPeMed@dlr.de
- ERA PeMed: ERAPeMed@agencerecherche.fr